Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain And Hypoglycemia Risk For Diabetes Patients
The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia for adult patients with diabetes. The data were presented at the American Diabetes Association"s 69th Scientific Sessions.
new payday loan lenders
Chain Restaurants Making Americans Fatter And Sicker Says Consumer Watchdog
America"s chain restaurants are making Americans fatter and sicker say consumer watchdog Center for Science in the Public Interest (CSPI) who
News of the day
Johns Hopkins Scientists Out A Gene For Gout
Having partnered last year with an international team that surveyed the genomes of 12,000 individuals to find a genetic cause for gout, Johns Hopkins scientists now have shown that the malfunctioning gene they helped uncover can lead to high concentrations of blood urate that forms crystals in joint tissue, causing inflammation and pain - the hallmark of this disease.
Mental Health

Survival In Prostate Cancer Patients >/=70 Years After Radical Prostatectomy And Comparison To Younger Patients

UroToday.com - In the online issue of the World Journal of Urology, a group headed by Professor Markus Hohenfellner compared the outcomes of radical prostatectomy (RP) in men younger and older than age 70 years. They suggest that in well-selected men over age 70 years, the outcomes are comparable. The study cohort consisted of 626 men who underwent RP at their institution between 1990 and 2006. A total of 526 were younger than 70 years old, and 100 were older than 70 years. The majority underwent radical retropubic RP and 46 underwent a perineal approach. The majority had a pelvic lymphadenectomy performed. Median patient age was 64.4 years, median PSA was 8.9ng/ml, and median follow-up was 5.3 years. For the analysis pre-op PSA, pathologic tumor stage, WHO tumor grading, margin status, time of PSA recurrence, time of distant metastatic recurrence, CaP specific and overall survival were considered. ECOG status was >1 in 7% of the older cohort compared to 2.3% of the younger men. While median age was almost 10 years older, percentage of organ-confined cancer, grade, positive lymph node and positive margin status did not differ. Median PSA-free survival was 10.2 years for the young men and not yet reached for the older men. The 10-year PSA-free survival was 51.8% for the young and 57.4% for the older men. The 10-year metastasis-free survival was 86.9% and 89.7% for the 70 year old patients, respectively. The 10-year prostate cancer specific survival was 92.3% and 97.6% for the young and old men, respectively. Median overall survival was 14 and 12.4 years and 10-year overall survival was 78.1% and 71.2% for the 70 year old patients, respectively. In multivariable analysis, there was no difference in any of the categories for clinical outcome where the age was a risk factor for adverse outcome. Pfitzenmaier J, Pahernik S, Buse S, Haferkamp A, Djakovic N, Hohenfellner M World J Urol. 2009 Apr 26. Epub ahead of print. doi:10.1007/s00345-009-0414-0 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009